Grades of newly occurring clinically notable abnormalities in white blood cells and absolute neutrophils from Week 20 through to the end of the study, by laboratory test and treatment (safety set).
| Laboratory Test | Secukinumab, n (%) | |||
|---|---|---|---|---|
| 25 mg, n = 18 | 75 mg, n = 23 | 150 mg, n = 115 | 300 mg, n = 60 | |
| White blood cells (total), 109/l | ||||
| Grade 1 (3–LLN) | 0 | 3 (13.0) | 6 (5.2) | 6 (10.0) |
| Grade 2 (2–3) | 0 | 1 (4.3) | 6 (5.2) | 0 |
| Grade 3 (1–2) | 0 | 1 (4.3) | 0 | 0 |
| Grade 4 (< 1) | 0 | 0 | 0 | 0 |
| Absolute neutrophils (segments + bands), 109/l | ||||
| Grade 1 (1.5–LLN) | 0 | 1 (4.3) | 3 (2.6) | 0 |
| Grade 2 (1.0–1.5) | 0 | 0 | 5 (4.3) | 1 (1.7) |
| Grade 3 (0.5–1.0) | 0 | 2 (8.7) | 5 (4.3) | 0 |
| Grade 4 (< 0.5) | 0 | 0 | 0 | 1 (1.7) |
LLN: lower limit of normal.